Elpida Therapeutics has partnered with Catalent, Inc. to enhance the manufacturing process for its AAV9 gene therapy targeting Spastic Paraplegia Type 50 (SPG50), a neurodegenerative disorder linked to AP4M1 mutations. This collaboration will ensure continued patient access and support the therapy’s progression toward regulatory submission. Catalent will utilize its advanced UpTempo™ AAV manufacturing platform to facilitate production, emphasizing its commitment to addressing significant unmet medical needs in ultra-rare diseases.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biospace.com/press-releases/catalent-and-elpida-therapeutics-enter-strategic-partnership-for-late-phase-aav-manufacturing
